Ncentrations progestin are Poly (ADP-ribose) polymerasefrom 108 mol / L to 107 mol / L. Because progestins have an inhibitory effect on the levels of VEGF and SDF-1 production by ESCs, it is suggested that progestins directly inhibit angiogenesis in human endometrium therapeutic doses. It is known that estrogen alone, the risk of endometrial hyperplasia and neoplasia increased Ht. In addition, anovulatory conditions such as polycystic ovary syndrome, Ngern the estrogen part of the menstrual cycle engaged Be obtained with a Incidence of endometrial cancer associated Hten. This risk is weakened by the addition of a progestin attenuated, And thus the r The progestin in the endometrium was also accepted in studies of hormone replacement therapy. In fact, progestins have been shown to be associated with the inhibition of growth of the endometrium associated. In addition, studies with mice showed M, Where f PR, not P compatibility available, the proliferative effect of E2 induced to reduce on the endometrium. In relation to the growth of the endometrium, in a previous study we found that SDF-1 is a candidate factor involved in talking about the interaction of epithelial stroma of human endometrium, and may be actively involved in proliferation. E2: M resembled have effects on angiogenesis and growth in the human endometrium via a path that both synergistic VEGF and SDF-1. These results suggest m Possible mechanisms for the growth inhibition of human endometrium by reducing SDF-1 and VEGF in the presence of progestin. Whatever the mechanism of inhibition of VEGF and SDF-1 production in the presence of progestins It is believed that E2-induced VEGF and SDF-production by an ER ESCs. Progestins are known to dinner down-regulation BX-912 702674-56-4 of ER came in the human endometrium in vivo and in vitro, and that inhibition of these angiogenic factors can k Be caused by lower ER. Otherwise occupied ER and PR ligands bind directly to DNA response element stero Of and recruits coregulators or activate the transcription of derivatives interaction19 norprogestone hydroxyprogesterone and 17a. 4 It has a strong impact and progestins antigonadotrophic moderate effects, but showed no androgen entfaltet.5 studies that examined the efficacy and reps Possibility of this drug that dienogest has a therapeutic effect on endometriosis was equivalent to Gn RH agonists, while w Dienogest that were associated with fewer symptoms my mortgage estrogens, such as hot flashes and decreased bone density 8 density.6 dienogest for the treatment of endometriosis is in Europ European Union, Japan and Australia approved. Uterine bleeding is a symptom Me relatively h Frequently, women who are treated with dienogest. Usually sets the duration and intensity t of the lower uterine bleeding as a treatment. Most women tolerate this symptom Me and discontinuation of treatment for uterine bleeding is massive but relatively rare.9 or leasing Ngerte menstrual k Nnten to cause serious Chemistry. In January 2009, a Change Warnings Fostamatinib and Precautions Took for the application of dienogest in Japan, which is consistent with reports of heavy menstrual bleeding in patients with adenomyosis and fibroids who were treated with dienogest, VER Published. Heavy menstrual bleeding is also mentioned in the special warning HNT.